Welcome to the e-CCO Library!

DOP79: Dose escalation of upadacitinib in Crohn’s Disease patients with inadequate response: Data from the randomised CELEST study
Year: 2020
Source: ECCO'20 Vienna
Authors: William Sandborn
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP79: Effect of vedolizumab on surgical rates in IBD: post hoc analysis from the GEMINI trials
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. G. Feagan*1, B. E. Sands2, R. Lirio3, T. Lissoos3, J. Wang3, D. Feng3, K. Lasch3

Created: Friday, 22 February 2019, 9:41 AM
DOP79: Effect of vedolizumab on surgical rates in IBD: Post hoc analysis from the GEMINI trials
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Trevor Lissoos
Created: Tuesday, 28 May 2019, 3:32 PM
Vedolizumab, Outcome measures
Files: 1
DOP79: Primary hypogammaglobulinemia with IBD-like features: An ECCO CONFER Multicenter Case Series
Year: 2021
Source: ECCO'21 Virtual
Authors: Albshesh, A.(1);Eder, P.(2);Ribaldone , D.G.(3);Oldenburg, B.(4);De Boer, N.K.(5);Mantzaris, G.J.(6); Savarino, E.V.(7);Dragoni , G.(8);Weisshof, R.(9);Truyens, M.(10);Festa, S.(11);Maillard, M.H.(12);Capirchio , L.(13);Filip, R.(14);Kopylov, U.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP79: Promising efficacy of biologicals and small molecules for microscopic colitis: results from a large real-life multicenter cohort
Year: 2024
Source: ECCO'24 Stockholm
Authors: Verstockt, Bram
Created: Tuesday, 30 April 2024, 5:03 PM
DOP80 Effectiveness of ustekinumab and vedolizumab in patients with Crohn’s disease refractory to anti-tumour necrosis factor: A multi-centre comparative study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

H. Alric1, A. Amiot2, J. Kirchgesner3, X. Tréton4, M. Allez5, Y. Bouhnik4, L. Beaugerie3, F. Carbonnel1, A. Meyer1

Created: Thursday, 30 January 2020, 10:12 AM
DOP80: Automatic detection of ulcers and erosions in PillCam™ Crohn’s capsule using a convolutional neural network
Year: 2021
Source: ECCO'21 Virtual
Authors: SaraivaJr., M.(1);Ribeiro, T.(1);Afonso, J.(1);Cardoso, H.(1);Ferreira, J.(2);Andrade, P.(1);Parente, M.(2);Jorge, R.(2);Lopes, S.(1);Macedo, G.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP80: Integrated tissue transcriptomic and serum proteomic interrogation reveals biomarkers for endoscopic improvement and histologic remission after JAK3/TEC inhibition with ritlecitinib (PF-06651600) in Ulcerative Colitis (UC) (Phase 2b Vibrato study)
Year: 2022
Source: ECCO'22
Authors: Hassan-ZahraeePhD, M.(1);Ye, Z.(1);Xi, L.(1);Banerjee, A.(1);He, W.(1);Dushin, E.(1);Lee, J.(1);Altintas, E.(2);Romatowski, J.(3);Leszczyszyn, J.(4);Danese, S.(5);Sandborn, W.J.(6);Banfield, C.(1);Gale, J.(7);Peeva, E.(7);Vincent, M.(7);Hyde, C.(1);Longman, R.(8);Hung, K.E.(7);
Created: Friday, 11 February 2022, 3:52 PM
DOP80: Multi-omic sequencing reveals distinctive gene expression and DNA methylation alterations as potential predictors of primary sclerosing cholangitis development in treatment-naïve paediatric ulcerative colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lawal, O.(1)*;Rodriguez-Sosa, A.(1);McDonnell, C.(1);Grant, L.(1);O'Brien, J.(2);Kel, A.(3);Dominik, A.(4);Stack, R.(5);Yochum, G.(6,7);Koltun, W.(6);Doherty, G.(5);Hussey, S.(8);
Created: Friday, 14 July 2023, 10:43 AM
DOP80: Oral curcumin is not more effective than placebo to prevent endoscopic postoperative recurrence in patients with Crohn's disease treated with concomitant thiopurines: the POPCUR trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Buisson*1, D. Laharie2, S. Nancey3, X. Hébuterne4, X. Roblin5, M. Nachury6, L. Peyrin-Biroulet7, M. Fumery8, F. Goutorbe1, D. Coban1, C. Allimant1, M. Reymond1, E. Vazeille1, B. Pereira1, M. Goutte1, G. Bommelaer1

Created: Friday, 22 February 2019, 9:41 AM
DOP80: Oral curcumin is not more effective than placebo to prevent endoscopic postoperative recurrence in patients with Crohn's disease treated with concomitant thiopurines: the POPCUR trial.
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Anthony Buisson
Created: Tuesday, 28 May 2019, 3:32 PM
Complementary therapies, Thiopurines (AZA / MP), Investigator-led
Files: 1
DOP80: Prevalence and factors associated with Inflammatory Bowel Disease (IBD) activity during pregnancy: updated data from the DUMBO Registry
Year: 2024
Source: ECCO'24 Stockholm
Authors: Chaparro, María
Created: Tuesday, 30 April 2024, 5:03 PM
DOP81 Time to loss of efficacy among patients in remission following induction treatment with tofacitinib 10 mg BID who reduced tofacitinib dose or discontinued tofacitinib in OCTAVE sustain
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.C. Dubinsky1, J.W. Chou2, C. Su3, W. Wang3, I. Modesto4, X. Guo3, S. Vermeire5

Created: Thursday, 30 January 2020, 10:12 AM
DOP81: Baseline whole-blood gene expression of TREM1 does not predict clinical or endoscopic outcomes following adalimumab treatment in patients with Ulcerative Colitis or Crohn’s Disease in the SERENE studies
Year: 2022
Source: ECCO'22
Authors: Verstockt, B.(1);Al Mahi, N.(2);Pivorunas, V.(3);Smaoui, N.(2);Guay, H.(3);Kennedy, N.A.(4);Hanauer, S.B.(5);Ferrante, M.(1);Panés, J.(6);Vermeire, S.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP81: Quality improvement by semi-automated benchmarking of a core outcome quality indicator set in Inflammatory Bowel Disease: A multicentric feasibility study
Year: 2021
Source: ECCO'21 Virtual
Authors: Bossuyt, P.(1);Baert, D.(2);Baert, F.(3);Hoefkens, E.(1);Huys, I.(2);Lembrechts, N.(1);De Jonckere, E.(3);Dewint, P.(2);Pouillon, L.(1)
Created: Wednesday, 2 June 2021, 4:12 PM